A trial of a new fertility drug has shown that it could improve the rate of embryo implantation during IVF and lead to a 7% increase in live births.

The pill, known as OXO-001, is designed to act directly on the lining of the womb to make it more receptive to the embryo being implanted. The findings raise hope for patients who have experienced repeated implantation failures during successive rounds of IVF.

“We are thrilled with the results of this trial, which highlight OXO-001’s potential to become the first therapeutic treatment to increase embryo implantation success, with a non-hormonal drug using a new mechanism of action, acting directly on the endometrium,” said Dr Ignasi Canals, chief scientific officer at Oxolife, the Spanish biotech company behind the trial, which is due to be presented at the European Society of Human Reproduction and Embryology’s 40th annual meeting in Amsterdam on Monday.

Read more on the findings here.